Search

Displaying results 1501 - 1510 of 10000 in total
  1. Target

    Ryanodine receptor 2

    go.drugbank.com/bio_entities/BE0005295
    TargetTransporterHumans

    Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering cardiac muscle contraction. Aberrant channel activation can lead ...

    Polypeptides: Ryanodine receptor 2Synonyms: Type 2 ryanodine receptor, Cardiac muscle ryanodine receptor
  2. Target

    Apolipoprotein B receptor

    go.drugbank.com/bio_entities/BE0005852
    TargetTransporterHumans

    Macrophage receptor that binds to the apolipoprotein B48 (APOB) of dietary triglyceride (TG)-rich lipoproteins (TRL) or to a like domain of APOB in hypertriglyceridemic very low density lipoprotein (HTG-VLDL

    Polypeptides: Apolipoprotein B receptorSynonyms: Apolipoprotein B-100 receptor, Apolipoprotein B-48 receptor
  3. Target

    Melanocortin receptor 4

    go.drugbank.com/bio_entities/BE0009682
    TargetHumans

    G protein-coupled receptor that binds melanocyte-stimulating hormones (alpha- and beta-MSH) and corticotropin/ACTH, which are peptide products of the POMC precursor (PubMed:12646665, PubMed:14764818, PubMed

    Polypeptides: Melanocortin receptor 4Function: corticotropin receptor activity
  4. Target

    Prosaposin receptor GPR37

    go.drugbank.com/bio_entities/BE0011479
    TargetHumans

    Acts as a receptor for several ligands including prosaposin, osteocalcin or neuroprotectin D1. … Acts as a receptor for osteocalcin (OCN) to regulate oligodendrocyte differentiation and central nervous system myelination.

    Polypeptides: Prosaposin receptor GPR37Synonyms: Parkin-associated endothelin receptor-like receptor, G protein-coupled receptor 37
  5. Target

    Relaxin receptor 1

    go.drugbank.com/bio_entities/BE0019700
    TargetHumans

    Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP.

    Polypeptides: Relaxin receptor 1Synonyms: Leucine-rich repeat-containing G protein-coupled receptor 7, Relaxin family peptide receptor 1
  6. Target

    Urotensin-2 receptor

    go.drugbank.com/bio_entities/BE0020904
    TargetHumans

    G protein-coupled receptor for the vasoactive neuropeptides urotensin-2 and urotensin-2B (PubMed:14550283).

    Polypeptides: Urotensin-2 receptorSynonyms: Urotensin II receptor, G protein-coupled receptor 14
  7. Drug

    Patent Blue

    go.drugbank.com/drugs/DB13967
    ApprovedInvestigational

    Patent blue is aniline dye and it is one of the most common dyes used.[A32573] It is a sodium or calcium salt of diethylammonium hydroxide inner salt. … [L1113] The isomer isosulphan is used in the United States for the same indications than patent blue.[A32574]

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    [L44667] Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. … Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    [A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer.[L34288] This mutation makes up >50% of all KRAS mutations. … Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.

  10. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    [A40025] From the LAMA group, revefenacin is the first once-daily nebulized LAMA treatment.[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] … Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA).